Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Novartis gene therapy poised to expand SMA treatment landscape, says GlobalData

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully achieved the primary endpoint in a Phase III STEER study (NCT05089656) involving pediatric patients aged 2–17 years with type II spinal muscular atrophy (SMA). These positive results have the potential to broaden the eligible patient population for this gene transfer […]
Read more

Immuno-oncology/ cancer therapeutics present strongest innovation pipeline in next five years, says GlobalData

Immuno-oncology (IO) drugs/ cancer therapeutics represent one of the most promising areas of medical innovation in the next five years, fundamentally transforming how cancer is treated, according to a survey conducted by GlobalData, a leading data and analytics company. In a recent GlobalData’s survey, “The State of the Biopharmaceutical Industry – 2025,” the largest proportion […]
Read more

Eli Lilly’s Zepbound holds potential to dominate obesity market, says GlobalData

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues. Zepbound’s superior efficacy and strategic market expansion suggest that the drug will dominate the obesity market, surpassing Novo Nordisk’s Wegovy (semaglutide), according to GlobalData, a leading data and analytics company. Recently, Eli Lilly announced […]
Read more

Zorifer poised to fill critical gap in treatment of advanced NSCLC with CNS metastases in China, says GlobalData

China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) specifically for the treatment of non-small cell lung cancer (NSCLC) with CNS metastases. Developed by Alpha Biopharma in collaboration with AstraZeneca, this new treatment option is expected to benefit EGFR-mutated NSCLC patients with different […]
Read more

Targeted therapies and improved diagnostics remain as unmet needs in T2-low asthma, says GlobalData

Despite advances in biologic therapies for severe asthma, significant unmet needs in asthma management remain, specifically with T-helper cell type 2 (T2)-low asthma, a subtype lacking typical inflammatory biomarkers. T2-low asthma presents unique challenges due to the absence of eosinophils and immunoglobulin E (IgE), which complicates both diagnosis and treatment. Insights from experts in the […]
Read more

Indian pharma companies focus on innovative research in foreign countries through dedicated entities, says GlobalData

Indian pharma players have increased their focus on innovative research and development (R&D). Historically, the majority of Indian companies used to execute their innovative research and development (R&D) from India. However, Indian companies have started establishing dedicated research companies in Western countries as well. Against this backdrop, the success of these dedicated research companies will […]
Read more

AbbVie’s tavapadon holds potential to become prominent treatment in dopamine agonist market, says GlobalData

AbbVie recently announced positive topline results from its pivotal Phase III TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson’s disease (PD). Tavapadon, the first and only D1/D5 partial agonist in the dopamine agonist class, is under investigation as a once-daily treatment for PD. The trial met both its primary and secondary […]
Read more

Celltrion leads biosimilars deals landscape in South Korea, finds GlobalData

South Korea has emerged as a global leader in the biopharmaceutical industry, driven by its advanced clinical research infrastructure and government support. Key companies like Celltrion and Samsung Bioepis dominate the biosimilars market, contributing significantly to the approvals and pipelines. Celltrion’s strong presence in deal-making further underscores South Korea’s growing influence in the global biosimilars […]
Read more

Unmet needs in chronic hand eczema present clear demand for new treatments, says GlobalData

Chronic hand eczema (CHE) is a persistent, inflammatory skin disorder characterized by redness and itching, significantly reducing quality of life (QoL). Although multiple treatments for CHE are available, significant unmet need remains in long-term disease management and symptom control unable to be addressed by the current therapies. Therefore, there is a clear demand for therapies […]
Read more

Toripalimab to fortify Dr. Reddy’s oncology portfolio as first checkpoint inhibitor for NPC in India, says GlobalData

Dr. Reddy’s Laboratories has recently become the first Indian company to launch checkpoint inhibitor Zytorvi (toripalimab) in collaboration with Shanghai Junshi Biosciences.  Zytorvi is a pioneering immuno-oncology therapy for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). This marks a transformative moment, bringing a next-generation PD-1 inhibitor to India and addressing significant unmet medical needs. With the […]
Read more
1 … 11 12 13 14 15 … 108